CLZ-8
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
Product Specifications
CAS Number
678158-55-9
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/clz-8.html
Purity
99.14
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
Molecular Formula
C22H23N3O2S
Molecular Weight
393.50
References & Citations
[1]Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8 (33) :54236-54242.|[2]Feng T, et al. CLZ-8, a potent small-molecular compound, protects radiation-induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2018 Jul;61:44-51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Mcl-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7065938 Inquire
Recombinant Ceratophyllum demersum ATP synthase subunit c, chloroplastic (atpH), partial
Sign In for Pricing
View Details